GRI Bio (GRI) Accounts Payables (2020 - 2026)
GRI Bio (GRI) posted quarterly Accounts Payables of $303000.0 for Q1 2026, down 77.74% year-over-year from $1.4 million in Q1 2025, and down 83.51% quarter-over-quarter from $1.8 million in Q4 2025.
GRI Bio (GRI) Accounts Payables (2020 - 2026) Analysis & Trends
GRI Bio's Accounts Payables history runs 7 years deep, the most recent figure standing at $303000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 77.74% year-over-year to $303000.0; the TTM figure through Mar 2026 stood at $303000.0 (down 77.74% YoY), while the FY2025 annual figure was $1.8 million, up 104.79% from the prior year.
- Accounts Payables for Q1 2026 stood at $303000.0, down from $1.8 million in the prior quarter.
- The five-year high for Accounts Payables was $1.8 million in Q4 2025, with the low at $303000.0 in Q1 2026.
- The 5-year median for Accounts Payables is $1.2 million (2022), against an average of $1.1 million.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables tumbled 83.04% in 2023, then soared 302.61% in 2024.
- GRI Bio's Accounts Payables stood at $1.3 million in 2022, then grew by 8.96% to $1.4 million in 2023, then plunged by 36.38% to $897000.0 in 2024, then surged by 104.79% to $1.8 million in 2025, then slumped by 83.51% to $303000.0 in 2026.
- Business Quant data shows GRI's Accounts Payables at $303000.0 in Q1 2026, $1.8 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | 526,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303,000.00 |
| Dec 31, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 897,000.00 |
| Sep 30, 2024 | 1.14 Mn |
| Jun 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 637,000.00 |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 988,000.00 |
| Jun 30, 2023 | 307,000.00 |
| Mar 31, 2023 | 528,000.00 |
| Dec 31, 2022 | 1.29 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.81 Mn |
| Mar 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 918,000.00 |
| Sep 30, 2021 | 488,000.00 |
| Jun 30, 2021 | 886,000.00 |